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ABSTRACT
Background. We investigated hyperactivity of the renin-angiotensin system (RAS) as a cause
of endothelial dysfunction in obese humans.
Methods. Thirty five healthy overweight (BMI  33.6  6.6 kg m 2) adults (33  10 years
old) without cardiovascular risk factors received valsartan (160 mg) orally daily or a match-
ing placebo for 6 weeks each.
Results. Baseline flow-mediated dilatation (FMD) and nitroglycerin-mediated dilatation
(NMD) were not altered by placebo or valsartan. However, fasting plasma insulin was sig-
nificantly decreased by valsartan compared to placebo (4.6  16.0 UmL1 versus 0.4 
11.6 UmL1, P  0.032) with no changes in glucose. A secondary analysis in patients with
elevated waist to hip ratios (ÿ0.85, n  18) showed an increase in FMD with valsartan.
Conclusions. Our findings suggest that angiotensin 2 receptor blockade may aid in the pre-
vention of diabetes even at the earliest stages of risk due solely to uncomplicated obesity.
The lack of an improvement in FMD does not support a central role of RAS-hyperactivity in
the etiology of the vascular dysfunction due solely to obesity. However, it is possible that
obese patients with central adiposity may improve FMD with RAS blockade, and future in-
vestigation is warranted in this subgroup. 
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INTRODUCTION
OBESITY, IN PARTICULAR CENTRAL ADIPOSITY, isassociated with insulin resistance and in-
dependently predicts the presence of vascular
endothelial dysfunction and reduced arterial
compliance.1,2 Even after accounting for other
aspects of the metabolic syndrome, excess adi-
posity per se causes endothelial dysfunction
(impaired nitric oxide-dependent vasomo-
tion).1–3 However, the biological mechanisms
underlying this relationship remain incom-
pletely described.
Even modest changes in traditional risk fac-
tors within “normal” ranges may negatively af-
fect the vasculature. With insulin resistance, a
concomitant impairment in vasodilatory in-
sulin signaling pathways within endothelial
cells may also play a more direct role in re-
ducing endothelial-dependent vasodilatation.2
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Moreover, fat cells release multiple adipokines
capable of affecting systemic vascular func-
tion.2,4 Among these factors, recent evidence
suggests that hyperactivity of the renin-an-
giotensin system (RAS) intrinsic to fat cells may
be particularly relevant.5–8 By contributing to
angiotensinogen and angiotensin 2 (AT2) con-
centrations, either systemically or in a local
paracrine fashion from perivascular fat, excess
adiposity could directly trigger both insulin re-
sistance and endothelial dysfunction.2,9 AT2
stimulates oxidative stress within the vascula-
ture via upregulation of NADPH oxidase and
thus reduces the bioavailability of nitric ox-
ide.10
Support for the physiological relevance of
this pathway comes from at least 2 recent stud-
ies. Weight loss reduces plasma levels of an-
giotensinogen, accompanied by a related de-
crease in blood pressure.8 AT2 receptor
blockade in obese patients with the metabolic
syndrome has also been shown to improve
brachial artery flow-mediated dilatation
(FMD).7 However, a significant portion of the
overweight patients in both studies had ac-
companying cardiovascular risk factors, such
as overt hypertension, and/or other aspects of
the metabolic syndrome (impaired fasting glu-
cose, atherogenic dyslipidemia). Therefore, the
direct role played solely by a hyperactive RAS
in altering systemic vascular function in un-
complicated obese states per se could not be
clearly evaluated due to the confounding ef-
fects of the associated risk factors on the RAS
and on levels of systemic oxidative stress.
The purpose of this study was to investigate
the ability of valsartan, a selective AT2 recep-
tor blocker, to improve the vascular dysfunc-
tion due to excess adiposity in patients with-
out any other aspects of the metabolic
syndrome. It was hypothesized that if upreg-
ulation of the RAS within adipocytes is play-
ing a direct etiologic role, blockade of the most
active component (AT2) by valsartan would
improve the previously described impairment
in brachial artery endothelial function (re-
duced FMD) in otherwise healthy overweight
adults.1 Additionally, we hypothesized that
the enhancement of metabolic insulin sensi-
tivity by AT2–blockade would be correlated
to the increase in FMD. This would reflect ei-
ther amelioration of a common underlying
causal risk factor such as oxidative stress
(common soil hypothesis), or that changes in
metabolic insulin sensitivity would subse-
quently yield an improvement in vascular en-
dothelial function.
METHODS
The study was prospectively performed at
the University of Michigan and approved by
its Institutional Review Board. Overweight
(body mass index [BMI]  27 kg  m2) non-
smoking adults without cardiovascular risk
factors (defined as blood pressure  140/90
mmHg and no history of hypertension; fasting
glucose  126 mg/dL and no history of dia-
betes; total cholesterol  240 mg/dL and no
history of hyperlipidemia; triglycerides  250
mg/dL, and no family history of known pre-
mature cardiovascular disease) were invited to
participate. No subject met the ATP3 criteria
for the metabolic syndrome. All subjects were
not taking any medication or substance known
to alter endothelial function for 6 weeks prior
to and during the study. Subjects signed in-
formed consent, had a physical examination,
and gave blood to assure they were healthy and
qualified for the study. We tested pregnancy,
lipids, basic chemistry, thyroid stimulating
hormone, insulin, and glucose. Body height,
weight, waist (thinnest circumference), hip (at
femoral heads), and waist circumference (at il-
liac crest), were obtained to determine eligibil-
ity and to characterize abdominal obesity. Sub-
jects who planned on initiating an exercise
routine during the trial were excluded. Eligible
subjects entered into a randomized, double-
blind, cross-over study (3 week washout) of
valsartan (160 mg orally daily) and placebo for
6 weeks each.
Testing sessions
There were 3 testing sessions involved: base-
line, after the first arm, and after the second
arm (the cross-over). Subjects fasted for at least
8 hours prior to each testing session. Subjects
arrived at approximately the same time of the
morning after fasting for more than 8 hours for
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all visits, and provided blood samples from an
antecubital vein.
C reactive protein (CRP) and lipoprotein sub-
class levels were measured by LipoScience In-
corporated (Raleigh, North Carolina). Lipopro-
teins were analyzed by nuclear magnetic
resonance spectroscopy, and high-sensitivity
CRP was analyzed by the Immuline 2000 ana-
lyzer (Diagnostic Product Corporation, Los An-
geles, California), as described elsewhere.11
Plasma leptin and adiponectin concentrations
were measured with a commercially available
enzyme-linked immunosorbent assay kit (Linco
Research, St. Louis, Missouri) according to the
manufacturer’s instructions.
Conduit vessel endothelial function was 
determined by brachial arterial FMD and ni-
troglycerin-mediated dilation (NMD) (endo-
thelial-independent vasomotion) using high-
resolution vascular ultrasonography by
standard methods in our laboratory as previ-
ously described.1 Subjects rested in a supine
position in a temperature-controlled room for
15 minutes before each vascular study. Blood
pressure was measured immediately prior to
the vascular studies and recorded as the av-
erage of 3 measurements (Omron 711AC, Om-
ron Healthcare, Inc., Bannockburn, IL). Sys-
temic vascular resistance and large and small
artery compliance were determined using
computerized arterial pulse waveform analy-
sis of the radial artery by tonometry (Hyper-
tension Diagnostics Incorporated). We
planned tonometry for all subjects, but the
measurement device was unavailable for
some subjects, which explains the different
sample size in the results.
Statistical analysis
The treatment effects were determined by
calculating the change from baseline for each
variable, and changes were compared by a
paired t-test. The study was a priori powered
to detect a minimum of 1.5% change in FMD
following valsartan treatment versus the
change after placebo, assuming a standard
deviation of FMD in each group  4.0%. All
analyses were performed using SPSS 13.0
with an   .05 level of statistical significance.
RESULTS
Table 1 shows the characteristics of the 35
subjects that completed the study. All partici-
pants were overweight, but normotensive and
without the metabolic syndrome. Baseline lab-
oratory values and their alterations by treat-
ment limb are shown in Table 2. Mean fasting
glucose values were within the normal range,
well below even the newly defined impaired
fasting glucose value (100 mgdL1). Patients
were not hyperlipidemic (normal total and low
density lipid [LDL]-cholesterol, and triglyc-
eride values). Mean high density lipid choles-
terol (HDL-C) level was modestly low; how-
ever the more detailed lipoprotein analyses
revealed an overall healthy basal profile with
a normal LDL particle size and number. As ex-
pected due to even uncomplicated obesity, fast-
ing insulin, C-reactive protein, and leptin were
mildly elevated, while adiponectin tended to
be low. Neither placebo nor valsartan signifi-
cantly altered any study parameter except for
fasting plasma insulin, which was significantly
reduced by valsartan versus the effect of
placebo. Concomitant with the reduction in in-
sulin, levels of fasting glucose remained statis-
tically unchanged and similar in both groups.
Table 3 demonstrates the vascular and he-
modynamic responses to treatments. Baseline
arterial diameter did not differ as a result of
placebo or valsartan treatment. Baseline pre-
treatment FMD was low versus the historical
normal value of nonobese healthy individuals
of similar age in our vascular laboratory (FMD
7% to 10%).1 However, there were no im-
provements in conduit artery endothelial func-
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TABLE 1. PATIENT CHARACTERISTICS
Total cohort
Mean  SD
Characteristics (n  35)
Age (years) 33  10
Male/Female (n) 6/29
Body Mass Index (kg m2) 33.6  6.6
Body Weight (kg) 97  22
Systolic Blood Pressure (mm Hg) 120  12
Diastolic Blood Pressure (mm Hg) 69  9
Waist (cm) 91  19
Hip (cm) 111  22
Waist circumference (cm) 100  19
tion (FMD), smooth muscle function (NMD), or
large and small vessel arterial compliance fol-
lowing valsartan or placebo. We planned
tonometry for all subjects, but the measure-
ment device was unavailable for some subjects,
which explains the different sample size in the
results. There was no difference in variables be-
tween subjects who had and did not have
tonometry evaluated. Results were not differ-
ent if we compared mean final FMD results
head-to-head via paired t-tests rather than the
change in response from baseline.
Based on previous reports,1 we have shown
that subjects with a high abdominal adiposity
(waist to hip ratio over 0.85) have a greater im-
pairment in FMD. We therefore performed a
secondary analysis among these centrally
obese subjects. Results in this specific subgroup
(n  18) showed a significant improvement in
FMD with valsartan versus placebo (FMD 1.7
 8.8% versus 1.9  8.7%, P  0.044).
As expected, blood pressure tended to be de-
creased in the valsartan limb, while systemic
vascular resistance was significantly reduced.
There were no reported adverse patient events
in either study limb or discontinuations due to
abnormalities in laboratory safety monitoring
(potassium and creatinine).
DISCUSSION
AT2 receptor blockade did not improve the
conduit arterial endothelial dysfunction or the
impaired vascular compliance that is directly
caused by uncomplicated obesity. This does
not support the hypothesis that RAS-hyperac-
tivity is a central underlying cause of the vas-
cular dysfunctions due solely to obesity. How-
ever, among individuals with central adiposity,
RAS-hyperactivity may be directly linked with
impaired vascular function. The finding that
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TABLE 2. LABORATORY CHANGES FROM BASELINE WITH PLACEBO AND VALSARTAN. VALUES REPRESENT THE MEAN  SD
Baseline (n  35)  Valsartan  Placebo n P
Glucose (mg/dL) 92  10 1.9  9.5 2.0  12.8 31 0.927
Insulin (U/mL) 23.0  22.6 4.6  16.0 0.4  11.6 30 0.032*
HDL Cholesterol (mg/dL) 38.7  9.9 0.64  4.7 0.1  4.4 28 0.516
Triglyceride (mg/dL) 95.9  39.6 6.7  29.3 6.5  31.4 28 0.979
Total LDL Particles (nmol/L) 1072  285 4.5  18.7 4.3  19.3 28 0.952
Small LDL Particles (nmol/L) 593  275 31  211 13  232 28 0.713
LDL Size (nm) 20.6  3.5 0.7  3.9 0.7  3.8 29 0.655
HDL Size (nm) 8.9  0.5 5.7  6.3 6.6  6.4 28 0.717
hs-CRP (mg/L) 7.5  10.6 1.6  7.8 0.4  4.6 28 0.435
Leptin (ng/mL) 31.5  10.1 0.4  5.6 1.6  5.4 25 0.126
Adiponectin (g/mL) 8.7  3.0 0.2  1.5 0.4  1.4 25 0.604
P value is for paired t-tests of the delta group differences in outcomes.
TABLE 3. VASCULAR CHANGES FROM BASELINE WITH PLACEBO AND VALSARTAN.
Baseline (n  35)  Valsartan  Placebo n P
Flow-mediated dilatation (%) 5.6  5.7 2.0 9.5 0.7  8.5 31 0.382
Nitroglycerin-mediated dilation (%) 19.9  6.4 0.71  0.1 0.97  6.7 28 0.405
Systemic Vascular Resistance
(dynes  sec  cm5) 1036  186 59  25 43  206 15 0.032*
Large Vessel Compliance
(10mlmm Hg1) 21.1  22.4 7.5  30.7 8.2  31.8 15 0.423
Small Vessel Compliance
(100mlmm Hg1) 10.0  3.7 1.9  2.4 1.1  3.4 15 0.802
Systolic Blood Pressure (mm Hg) 120  12 2.8  9.3 0.5  9.8 24 0.108
Diastolic Blood Pressure (mm Hg) 69  9 1.4  12.1 1.5  10.2 24 0.186
Values represent the mean  SD
P value is for paired t-tests of the delta group differences in outcomes.
valsartan improved FMD in this subgroup re-
quires confirmation in future studies. Never-
theless, our results confirm and extend previ-
ous observations that AT2 blockade improves
metabolic insulin sensitivity (as determined by
a reduction in fasting plasma insulin concomi-
tant with a stable glucose). 9,12 The novel find-
ing of this study is that this beneficial action oc-
curred even in normoglycemic, normotensive
healthy overweight adults without the meta-
bolic syndrome. This suggests that RAS-hy-
peractivity may play a role in the mechanisms
of insulin resistance even in uncomplicated
obesity. Furthermore, it can be speculated that
valsartan may be beneficial in the prevention
of diabetes even at the very earliest stages of
risk, such as overweight individuals with nor-
mal glucose and blood pressure values.
Obesity directly causes endothelial dysfunc-
tion by a variety of mechanisms.1–3 Our find-
ing of a reduced brachial FMD in the study sub-
jects compared to the usual normal values of
healthy non-obese adults in our laboratory
(FMD  7%–10%) confirms this association.1
Among the variety of biological explanations,
we investigated the direct role of RAS-hyper-
activity due to obesity. 5–8 It was hypothesized
that healthy overweight individuals may have
impaired vascular function triggered by
higher-than-normal vascular AT2 activity from
either a systemic hormonal effect from visceral
adipocyte release of angiotensinogen or AT2
and/or from RAS-hyperactivity within local
peri-vascular fat. The lack of increase in
brachial FMD after effective AT2 blockade with
valsartan (demonstrated by reduced blood
pressure and vascular resistance) does not sup-
port this primary hypothesis. In addition, if
subtle defects in insulin signaling (vascular
and/or metabolic insulin resistance) secondar-
ily trigger the endothelial dysfunction of un-
complicated obesity, we would have antici-
pated a parallel increase in both insulin
sensitivity and vascular function, which was
not found. The negative findings of this study
suggest that other mechanisms related to ex-
cess adiposity must be promoting the vascular
dysfunction in overweight individuals without
the metabolic syndrome.
AT2 blockade has been shown to improve
metabolic insulin sensitivity by several puta-
tive mechanisms and to prevent the onset of di-
abetes mellitus among hypertensive individu-
als. 9,12 As far as we are aware, our findings are
the first to demonstrate that AT2 blockade can
enhance insulin sensitivity, as determined by a
reduction in fasting insulin with stable blood
glucose, in otherwise healthy normoglycemic
overweight adults in the absence of the meta-
bolic syndrome. Weight loss, dietary changes,
and exercise may prevent or delay diabetes in
at-risk patients. Long term adherence to
lifestyle changes is likely to be poor. These find-
ings provide evidence that valsartan, a safe and
well-tolerated medication, may be effective for
the prevention of diabetes even among healthy
overweight adults at the earliest stages of dis-
ease risk.
Brachial FMD nonsignificantly trended to-
ward an increase in the valsartan limb. The
study may have been underpowered to detect
small improvements. We had anticipated a
smaller standard deviation (4.0% versus 9.0%)
in the FMD treatment change. Post hoc power
calculations demonstrate that with this sample
size we could determine with 80% power a
4.5% change in FMD. It is possible that smaller,
yet physiological meaningful improvements in
endothelial function (i.e., FMD of 2.0%) did
occur by AT2 blockade (type 2 error). Never-
theless, many studies of similar size and dura-
tion have demonstrated improvements in en-
dothelial function when clinically relevant in
other disease states. Any change in this study
was thus of relatively small magnitude. Larger
studies may settle the issue whether inade-
quate sample size is to blame for the negative
finding, or if this truly reflects that 1 or more
other biological mechanisms are more primar-
ily responsible for linking uncomplicated obe-
sity with endothelial dysfunction.3 It is unlikely
that the dose and duration of valsartan treat-
ment was inadequate to test this hypothesis, as
both the blood pressure and vascular resistance
reductions demonstrated a physiological effect
of the medication. However, in theory a study
of longer duration and/or using a higher dose
of valsartan could be required to yield im-
provements in FMD. We also can not exclude
the possibility that differences in the phase of
menstrual cycle during testing biased results to
the null. In addition, gold standard methods
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(e.g., glucose clamp) to measure metabolic in-
sulin sensitivity were not performed. A re-
duction in fasting plasma insulin (with a sta-
ble blood glucose) is an indirect measure of
metabolic insulin sensitivity with several lim-
itations and cannot distinguish the biological
etiology of the metabolic change (i.e., altered
insulin secretion versus improved systemic
responsiveness). However, it has been
demonstrated that fasting insulin is a valid
and useful measures of insulin sensitivity that
provides most of the relevant physiological
information provided by more invasive tech-
niques. 13–15 Calculated indices such as glu-
cose/insulin or HOMAIR have been shown to
not add to the accuracy of fasting insulin con-
centration to predict metabolic insulin sensi-
tivity in nondiabetic patients with a stable
blood glucose12,13,14 and were not performed.
Therefore, we believe the reduction in fasting
insulin by valsartan does represent a mean-
ingful improvement in insulin sensitivity for
the methodological reasons listed and be-
cause it corroborates the many previous stud-
ies that have confirmed that RAS-blockade
does indeed enhance peripheral insulin uti-
lization along with metabolic insulin sensi-
tivity.
The results from a secondary analysis among
patients with an elevated waist to hip ratio are
interesting. It is possible that patients with ab-
dominal obesity have an activated RAS that is
directly causing systemic vascular function and
will therefore show improved FMD with val-
sartan treatment. Had we included only pa-
tients with an increased waist to hip ratio over
0.85 (as per the associations found in our ini-
tial study)1, the results linking FMD with block-
ade of RAS may have been positive for the en-
tire overall study cohort. However, this was a
not a pre-specified analysis and will require
further investigation.
Our results do not support the hypothesis
that hyperactivity of RAS plays a central role
in the vascular dysfunctions due solely to un-
complicated obesity. Further studies are war-
ranted among patients with excess abdominal
adiposity. The finding that metabolic insulin
sensitivity improves in this healthy group of
normoglycemic overweight adults without the
metabolic syndrome supports the notion that
the RAS may play a role in obesity-related in-
sulin resistance and that valsartan may be an
effective preventative modality even at the ear-
liest stages of diabetes risk.
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